535-0901-00L  From A to Z in Drug Discovery and Development

SemesterSpring Semester 2021
LecturersJ. Hall, K.‑H. Altmann, M. Detmar, R. Schibli, H. U. Zeilhofer
Periodicityyearly recurring course
CourseDoes not take place this semester.
Language of instructionEnglish



Courses

NumberTitleHoursLecturers
535-0901-00 SFrom A to Z in Drug Discovery and Development
Does not take place this semester.
The next course will take place in autumn semester 2021.
2 hrsJ. Hall, K.‑H. Altmann, M. Detmar, R. Schibli, H. U. Zeilhofer

Catalogue data

AbstractThe lecture series takes place at the ETH Hönggerberg and covers a variety of major activities involved in drug discovery: selecting drug targets, technologies used in drug discovery, small, medium and large drugs, objectives of the medicinal chemist, assessing drug safety, principles of personalized medicine, designing clinical trials, how intellectual property is protected, as well as others.
ObjectiveThe objective of the course is to gain a global understanding of most of the important phases in the discovery and development of modern synthetic and biological drugs, from the first activities to clinical trials. The lecture is intended for students that have an interest in the area and/or may consider a career working in drug discovery. This lecture course complements knowledge and experience gained in the research project performed by the PhD student.
ContentFifteen two hour lectures for life-science PhD students, given by experts from the ETH, UZH, USZ and the pharmaceutical industry.
Introduction to the modern drug discovery process - Principles of drug pharmacokinetics and drug metabolism - Computer sciences in drug discovery - Drug targets - In vitro methods in drug discovery - Natural products in drug discovery - Medicinal chemistry: Chemical lead selection/optimization - Nucleic acid-based drugs - Antibodies and therapeutic proteins: Targets and drugs - In vivo molecular imaging in drug discovery - Personalized medicine in drug discovery and development - Drug formulation: Key development consideration, Current new APIs challenges and FDA rising standards - Preclinical safety, adverse drug events and drug-drug interactions - Clinical development steps including trial design - Intellectual property in drug discovery and development
Lecture notesScripts to be uploaded into ILIAS
LiteratureTo be distributed during the lecture
Prerequisites / NoticeFormally none, but a basic understanding in biochemistry, physiology and chemistry is highly desirable as it will certainly help to get the most from the lectures.

Performance assessment

Performance assessment information (valid until the course unit is held again)
Performance assessment as a semester course
ECTS credits2 credits
ExaminersJ. Hall, K.-H. Altmann, J. Baumgartner, M. Detmar, D. Neri, R. Schibli, H. U. Zeilhofer
Typeungraded semester performance
Language of examinationEnglish
RepetitionRepetition only possible after re-enrolling for the course unit.

Learning materials

No public learning materials available.
Only public learning materials are listed.

Groups

No information on groups available.

Restrictions

There are no additional restrictions for the registration.

Offered in

ProgrammeSectionType
Doctoral Department of Chemistry and Applied BiosciencesDoctoral Studies in Pharmaceutical SciencesZInformation